Wet AMD Clinical Trials
Opthea has completed a randomised, controlled, double-masked Phase 2b clinical trial in 366 treatment-naïve wet AMD patients investigating the VEGF-A inhibitor Lucentis® (ranibizumab) administered in combination with OPT-302 compared to Lucentis® administered alone. The trial met the primary endpoint, with OPT-302 administered in combination with Lucentis® demonstrating a statistically significant superior mean gain in visual acuity over Lucentis monotherapy at week 24.
- Phase 2b wet AMD clinical trial: OPT-302-1002 (COMPLETED)
- Phase 1/2a wet AMD clinical trial: OPT-302-1001 (COMPLETED)
DME Clinical Trials
Opthea has reported outcomes from a Phase 1b dose-escalation clinical trial of OPT-302 administered in combination with the VEGF-A inhibitor Eylea® (aflibercept). Dose-responsive improvements in visual acuity were observed in patients treated with increasing doses of OPT-302 (0.3, 1.0, 2.0 mg) administered in combination with Eylea (2 mg). Opthea has also reported outcomes from a Phase 2a clinical trial in patients with treatment-refractory, persistent DME, demonstrating improved clinical outcomes in patients treated with OPT-302 in combination with Eylea®.
- Phase 1/2a DME clinical trial: OPT-302-1003 (COMPLETED)